Another Dual-NRTI Backbone

Backbone matters

TRUVADA® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg) is for patients weighing ≥35 kg (77 lbs) with HIV-1 in combination with other antiretroviral agents1

Prescribing considerations: Do not use TRUVADA as a component of a triple nucleoside regimen or coadminister with other products containing emtricitabine, tenofovir alafenamide, tenofovir disoproxil fumarate (tenofovir DF), or lamivudine. Use of TRUVADA in treatment experienced HIV-1 infected patients should be guided by laboratory testing and treatment history.1

A dual-NRTI backbone is a key component
of HIV-1 treatment2

  • All DHHS-recommended regimens for treatment-naive adults are built on a dual-NRTI backbone2
  • The backbone generally accounts for 2/3 of a standard antiretroviral treatment2
  • Backbones have been a part of ARV regimens since 1996. The backbone TRUVADA was approved in 2004 and has been prescribed for more than a decade2

Please see Important Safety Information for TRUVADA,
including BOXED WARNING, below